← Leaderboards
Amarnath Natarajan
University Of Nebraska Medical Center
$8,497,174
Attributed
$9,961,450
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,961,450 · 8
By mechanism
R01$8,615,825 · 4
R21$833,313 · 2
P20$487,312 · 1
R03$25,000 · 1
Top collaborators
- Raymond C Bergan5 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Raymond C Bergan$7,632,509
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsMalignant NeoplasmsProgramsSmall MoleculeTherapeutic TargetGrowthAnalogCellsSignal TransductionMutationTumorBinding SitesDesignBindingPharmaceutical PreparationsApoptosisStructureMediatingToxic EffectPhosphorylationStructure-Activity RelationshipTumor GrowthInhibitor/AntagonistBase
Grant awards (33)
Preventing invasive prostate cancer$1,607,348
R01 · FY2025 · CA
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers$383,749
R01 · FY2025 · CA · contact PI
UPR Activators for Cancer Therapy$351,131
R01 · FY2025 · CA · contact PI
Probes, Inhibitors, and PROTACs (PIP) Core$149,241
P20 · FY2025 · GM · contact PI
Preventing invasive prostate cancer$138,214
R01 · FY2025 · CA
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers$1
R01 · FY2025 · CA · contact PI
Preventing invasive prostate cancer$508,994
R01 · FY2024 · CA
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers$364,563
R01 · FY2024 · CA · contact PI
UPR Activators for Cancer Therapy$333,575
R01 · FY2024 · CA · contact PI
Probes, Inhibitors, and PROTACs (PIP) Core$152,311
P20 · FY2024 · GM · contact PI
Regulation of extracellular proteases in prostate cancer progression to a metastatic phenotype$138,214
R01 · FY2024 · CA
Preventing invasive prostate cancer$535,783
R01 · FY2023 · CA
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers$383,750
R01 · FY2023 · CA · contact PI
UPR Activators for Cancer Therapy$344,109
R01 · FY2023 · CA · contact PI
Probes, Inhibitors, and PROTACs (PIP) Core$185,760
P20 · FY2023 · GM · contact PI
UPR Activators for Cancer Therapy$350,560
R01 · FY2022 · CA · contact PI
PROTACs for pancreatic cancer therapy$393,400
R21 · FY2020 · CA · contact PI
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers$344,094
R01 · FY2020 · CA · contact PI
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers$333,770
R01 · FY2019 · CA · contact PI
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers$344,094
R01 · FY2018 · CA · contact PI
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers$344,094
R01 · FY2017 · CA · contact PI
Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers$355,646
R01 · FY2016 · CA · contact PI
Phosphorylated Form of Activated IKKbeta and Pancreatic Cancer$196,403
R21 · FY2015 · CA · contact PI
Phosphorylated Form of Activated IKKbeta and Pancreatic Cancer$48,937
R21 · FY2015 · CA · contact PI
Phosphorylated Form of Activated IKKbeta and Pancreatic Cancer$163,669
R21 · FY2014 · CA · contact PI
Phosphorylated Form of Activated IKKbeta and Pancreatic Cancer$30,904
R21 · FY2014 · CA · contact PI
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics$270,598
R01 · FY2012 · CA · contact PI
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics$270,598
R01 · FY2011 · CA · contact PI
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics$278,966
R01 · FY2010 · CA · contact PI
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics$90,477
R01 · FY2010 · CA · contact PI
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics$273,497
R01 · FY2009 · CA · contact PI
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics$270,000
R01 · FY2008 · CA · contact PI
HTS to Identify Small Molecule Inhibitors of Phospho-Specific Protein-Protein Int$25,000
R03 · FY2007 · MH · contact PI